VirtualScreeningofMultitargetKinaseInhibitorsstatisticallearningmethodknearestneighbor(kNN),35andamachine-learningmethodprobabilisticneuralnetworks(PNN)36againstthesamesetsofdual-andnon-dualkinaseinhibitorsandthefullsetorsubsetofthe1.02millionZincclean-leadsdataset(Zinc-CLD).37Thespeci cindicatorstobecomparedarethedual-inhibitoryieldsforbothintragroupandintergroupdual-kinaseinhibitors,andthefalse-hitratesfornon-dualkinaseinhibitorsandtheZinc-CLDdataset,whichenableobjectiveassessmentofthecapabilityofC-SVMwithrespecttothoseofthepopularaswellasmachinelearningbasedVSmethods.
Methods
CompoundCollection,TrainingandTestingDataSets,MolecularDescriptors.Atotalof233-1,316non-dual-inhibitorsofEGFR,VEGFR,PDGFR,FGFR,Src,Lck,CDK1,CDK2,andGSK3,and41-230dual-inhibitorsofEGFR-PDGFR,EGFR-FGFR,EGFR-Src,VEGFR-Lck,PDGFR-FGFR,PDGFR-Src,Src-Lck,CDK1-CDK2,CDK1-GSK3,CDK2-GSK3,andCDK1-VEGFR,eachwithIC50e10µM,werecollected48Dual-inhibitorsfromtheliterature38-47andtheBindingDBdatabase.andnon-dual-inhibi-torsofakinasepairrefertoinhibitorsofbothandoneofthetwokinasesrespectivelyregardlessoftheiractivities
(35)Li,J.;Gramatica,P.Classi cationandVirtualScreeningof
AndrogenReceptorAntagonists.J.Chem.Inf.Model.2010,50,861–74.
(36)Derksen,S.;Rau,O.;Schneider,P.;Schubert-Zsilavecz,M.;
Schneider,G.VirtualscreeningforPPARmodulatorsusingaprobabilisticneuralnetwork.ChemMedChem2006,1(12),1346–50.
(37)Irwin,J.J.;Shoichet,B.K.ZINCsafreedatabaseofcommercially
availablecompoundsforvirtualscreening.J.Chem.Inf.Model.2005,45(1),177–82.
(38)Noble,M.E.;Endicott,J.A.;Johnson,L.N.Proteinkinase
inhibitors:insightsintodrugdesignfromstructure.Science2004,303(5665),1800–5.
(39)Vema,A.;Panigrahi,S.K.;Rambabu,G.;Gopalakrishnan,B.;
Sarma,J.A.;Desiraju,G.R.DesignofEGFRkinaseinhibitors:aligand-basedapproachanditscon rmationwithstructure-basedstudies.Bioorg.Med.Chem.2003,11(21),4643–53.
(40)Yu,H.;Wang,Z.;Zhang,L.;Zhang,J.;Huang,Q.Pharmacophore
modelingandinsilicoscreeningfornewKDRkinaseinhibitors.Bioorg.Med.Chem.Lett.2007,17(8),2126–33.
(41)Matsuno,K.;Ichimura,M.;Nakajima,T.;Tahara,K.;Fujiwara,
S.;Kase,H.;Ushiki,J.;Giese,N.A.;Pandey,A.;Scarborough,R.M.;Lokker,N.A.;Yu,J.C.;Irie,J.;Tsukuda,E.;Ide,S.;Oda,S.;Nomoto,Y.Potentandselectiveinhibitorsofplatelet-derivedgrowthfactorreceptorphosphorylation.1.Synthesis,structure-activityrelationship,andbiologicaleffectsofanewclassofquinazolinederivatives.J.Med.Chem.2002,45(14),3057–66.
(42)Thompson,A.M.;Connolly,C.J.;Hamby,J.M.;Boushelle,S.;
Hartl,B.G.;Amar,A.M.;Kraker,A.J.;Driscoll,D.L.;Steinkampf,R.W.;Patmore,S.J.;Vincent,P.W.;Roberts,B.J.;Elliott,W.L.;Klohs,W.;Leopold,W.R.;Showalter,H.D.;Denny,W.A.3-(3,5-Dimethoxyphenyl)-1,6-naphthyridine-2,7-diaminesandrelated2-ureaderivativesarepotentandselectiveinhibitorsoftheFGFreceptor-1tyrosinekinase.J.Med.Chem.2000,43(22),4200–11.
articles
againstotherkinases.Table1summarizesthestatisticsoftheseinhibitorsandMDDRcompoundssimilartoatleastonedual-inhibitor.Figure1showstheVenngraphofourcollecteddual-inhibitors,the11evaluatedkinasepairsandnon-dual-inhibitorsofthe9evaluatedkinases.Asfewnoninhibitorshavebeenreported,putativenoninhibitorsofeachkinaseweregeneratedbyusingourpublishedmethodthatrequiresnoknowledgeofinactivecompoundsoractivecompoundsofothertargetclassesandenablesmoreex-pandedcoverageofthe“noninhibitor”chemicalspace.12,13First,13.56millionPubChemand168thousandMDDRcompoundswereclusteredinto8,993compoundfamiliesofsimilarmoleculardescriptors,49whichareconsistentwiththereported12,800compound-occupyingneurons(regionsoftopologicallyclosestructures)for26.4millioncompoundsofupto11atoms,50and2,851clustersfor171,045naturalproducts.51Atotalof42,670-44,115compoundsextractedfromthe8,534-8,823families(5perfamily)thatcontainnoknowninhibitorwereusedastheputativenoninhibitors.
(43)Dalgarno,D.;Stehle,T.;Narula,S.;Schelling,P.;vanSchrav-endijk,M.R.;Adams,S.;Andrade,L.;Keats,J.;Ram,M.;Jin,L.;Grossman,T.;MacNeil,I.;Metcalf,C.,3rd;Shakespeare,W.;Wang,Y.;Keenan,T.;Sundaramoorthi,R.;Bohacek,R.;Weigele,M.;Sawyer,T.StructuralbasisofSrctyrosinekinaseinhibitionwithanewclassofpotentandselectivetrisubstitutedpurine-basedcompounds.Chem.Biol.DrugDes.2006,67(1),46–57.(44)Abbott,L.;Betschmann,P.;Burchat,A.;Calderwood,D.J.;Davis,
H.;Hrnciar,P.;Hirst,G.C.;Li,B.;Morytko,M.;Mullen,K.;Yang,B.DiscoveryofthienopyridinesasSrc-familyselectiveLckinhibitors.Bioorg.Med.Chem.Lett.2007,17(5),1167–71.(45)Showalter,H.D.;Sercel,A.D.;Leja,B.M.;Wolfangel,C.D.;
Ambroso,L.A.;Elliott,W.L.;Fry,D.W.;Kraker,A.J.;Howard,C.T.;Lu,G.H.;Moore,C.W.;Nelson,J.M.;Roberts,B.J.;Vincent,P.W.;Denny,W.A.;Thompson,A.M.Tyrosinekinaseinhibitors.6.Structure-activityrelationshipsamongN-and3-substituted2,2′-diselenobis(1H-indoles)forinhibitionofproteintyrosinekinasesandcomparativeinvitroandinvivostudiesagainstselectedsulfurcongeners.J.Med.Chem.1997,40(4),413–26.
(46)Asano,T.;Yoshikawa,T.;Usui,T.;Yamamoto,H.;Yamamoto,
Y.;Uehara,Y.;Nakamura,H.Benzamidesandbenzamidinesasspeci cinhibitorsofepidermalgrowthfactorreceptorandv-Srcproteintyrosinekinases.Bioorg.Med.Chem.2004,12(13),3529–42.
(47)Caballero,J.;Fernandez,M.;Saavedra,M.;Gonzalez-Nilo,F.D.
2DAutocorrelation,CoMFA,andCoMSIAmodelingofproteintyrosinekinases’inhibitionbysubstitutedpyrido[2,3-d]pyrimidinederivatives.Bioorg.Med.Chem.2008,16(2),810–21.
(48)Liu,T.;Lin,Y.;Wen,X.;Jorissen,R.N.;Gilson,M.K.
BindingDB:aweb-accessibledatabaseofexperimentallydeter-minedprotein-ligandbindingaf nities.NucleicAcidsRes.2007,35(Databaseissue),D198–201.
(49)Oprea,T.I.;Gottfries,J.Chemography:theartofnavigatingin
chemicalspace.J.Comb.Chem2001,3(2),157–66.
(50)Fink,T.;Reymond,J.-L.VirtualExplorationoftheChemical
Universeupto11AtomsofC,N,O,F:Assemblyof26.4MillionStructures(110.9MillionStereoisomers)andAnalysisforNewRingSystems,Stereochemistry,PhysicochemicalProperties,CompoundClasses,andDrugDiscovery.J.Chem.Inf.Model.2007,47(2),342–53.
VOL.7,NO.5MOLECULARPHARMACEUTICS1549
Synthesis and Characterization of Pyrazoleanthrone Derivatives as Aurora A Kinase Inhibitors_生产/经营管理_经管营销_专业资料。Chem.Res.Chin.Univ.2013.29(6)...
Synthesis and Characterization of Pyrazoleanthrone Derivatives as Aurora A Kinase Inhibitors_生产/经营管理_经管营销_专业资料。Chem.Res.Chin.Univ.2013.29(6)...
热门文档